HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.

Abstract
Despite the preclinical success of adoptive therapy with T cells bearing chimeric nanoconstructed antigen receptors (CARs), certain limitations of this therapeutic approach such as the immunogenicity of the antigen binding domain, the emergence of tumor cell escape variants and the blocking capacity of soluble antigen still remain. Here, we address these issues using a novel CAR binding moiety based on the oligoclonal camelid single domain antibodies. A unique set of 13 single domain antibodies were selected from an immunized camel phage library based on their target specificity and binding affinity. A combination of these single domain antibodies was used to generate four tumor associated glycoprotein (TAG-72)-specific CARs harboring an identical antigen binding site, but with different signaling and spacer domains. Although all four CARs were functionally active against the TAG-72 expressing tumor cells, the combination of CD3ΞΆ, OX40, CD28 as well as the CH3-CH2-hinge-hinge domains most efficiently triggered T cell activation. Importantly, CAR mediated functions were not blocked by the soluble TAG-72 antigen at a supraphysiological concentration. Our approach may have the potential to reverse multiple tumor immune evasion mechanisms, avoid CAR immunogenicity, and overcome problems in cancer gene therapy with engineered nanoconstructs.
AuthorsZahra Sharifzadeh, Fatemeh Rahbarizadeh, Mohammad A Shokrgozar, Davoud Ahmadvand, Fereidoun Mahboudi, Fatemeh Rahimi Jamnani, S Moein Moghimi
JournalCancer letters (Cancer Lett) Vol. 334 Issue 2 Pg. 237-44 (Jul 01 2013) ISSN: 1872-7980 [Electronic] Ireland
PMID22902507 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Antigens, Neoplasm
  • Glycoproteins
  • Immunoglobulin G
  • Peptide Library
  • Receptors, Antigen
  • Recombinant Fusion Proteins
  • Single-Domain Antibodies
  • tumor-associated antigen 72
Topics
  • Animals
  • Antibody Specificity
  • Antigens, Neoplasm (genetics, immunology)
  • Camelids, New World
  • Carcinoma, Squamous Cell (immunology, therapy)
  • Colonic Neoplasms (immunology, therapy)
  • Genetic Engineering (methods)
  • Glycoproteins (genetics, immunology)
  • HT29 Cells
  • Humans
  • Immunoglobulin G (genetics, immunology)
  • Immunotherapy, Adoptive (methods)
  • Leukemia, T-Cell (immunology, therapy)
  • Lymphocyte Activation
  • Peptide Library
  • Receptors, Antigen (genetics, immunology)
  • Recombinant Fusion Proteins (genetics, immunology)
  • Signal Transduction
  • Single-Domain Antibodies (genetics, immunology)
  • T-Lymphocytes (immunology, physiology)
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: